SUBSCRIBE Blog with us: BLOGbiotech

GEN News Highlights

• Email
• Print
• Share
• More GEN News Highlights

Oct 21 2008, 11:08 AM EST

Bayer Pays $4M Upfront to Use ImmunoGen’s Technology for a Solid Tumor Target

GEN News Highlights

Bayer HealthCare licensed exclusive, worldwide rights to ImmunoGen's tumor-activated prodrug (TAP) technology to develop cancer drugs to a particular target found on solid tumors.

ImmunoGen will receive an upfront payment of $4 million. For each compound developed and marketed by Bayer under this collaboration, ImmunoGen is entitled to milestones totaling $170.5 million plus royalties on commercial sales.

ImmunoGen will also be financially compensated for the production of any preclinical and nonpivotal clinical materials and for any product development research done under this deal. Bayer HealthCare is responsible for the research, development, manufacturing, and marketing of products resulting from this license.

ImmunoGen’s technology can enhance the anticancer activity of manufactured proteins. The company reports that its cell-killing agents are highly potent and can be affixed to such proteins using ImmunoGen linkers, which keep the agent attached and inactive until the TAP compound has bound to and entered a cancer cell. There, the cell-killing agent releases to kill the cancer cell.

• Email
• Print
• Share
• More GEN News Highlights

Comment on this News:

Name:
Title:
Comment:
	HELP US FIGHT SPAMMING ROBOTS by answering the following simple question. It will verify you as a legitimate user wishing to post a comment. Thank you for your cooperation.

CAREER CENTER

WEBINARS

PODCASTS

MOST POPULAR